Evidence map›Paper›PMID 31023861›Full record

ArticleThe oncologist2019

Clinical Characteristics and Survival of Patients with Malignant Ovarian Tumors in Addis Ababa, Ethiopia.

Swantje Piszczan, Dawit Desalegn, Hezkiel Petros, Mengistu Gurmu, Eric Sven Kroeber, Adamu Addissie, Rafael Mikolajczyk, Rahel G Ghebre, Assefa Mathewos, Christoph Thomssen and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Antiproliferative Effects of Alkaloids from the Bulbs ofEvidence-based complementary and alternative medicine : eCAM · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Swantje PiszczanDepartment of Gynecology, Martin-Luther-University, Halle an der Saale, Germany.
Dawit DesalegnDepartment of Gynecology and Obstetrics, Addis Ababa University, Ethiopia.
Hezkiel PetrosDepartment of Gynecology and Obstetrics, Addis Ababa University, Ethiopia.
Mengistu GurmuDepartment of Gynecology and Obstetrics, Addis Ababa University, Ethiopia.
Eric Sven KroeberInstitute of Medical Epidemiology, Biostatistics and Informatics, Martin-Luther-University, Halle an der Saale, Germany.
Adamu AddissieRadiotherapy Center, School of Medicine, Addis Ababa University, Ethiopia.
Rafael MikolajczykInstitute of Medical Epidemiology, Biostatistics and Informatics, Martin-Luther-University, Halle an der Saale, Germany.
Rahel G GhebreDepartment of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, Minnesota, USA.
Assefa MathewosRadiotherapy Center, School of Medicine, Addis Ababa University, Ethiopia.
Christoph ThomssenDepartment of Gynecology, Martin-Luther-University, Halle an der Saale, Germany.
Ahmedin JemalAmerican Cancer Society, Atlanta, Georgia, USA.
Eva Johanna KantelhardtDepartment of Gynecology, Martin-Luther-University, Halle an der Saale, Germany Eva.kantelhardt@uk-halle.de.ORCID 0000-0001-7935-719X
Addis Ababa University · ETMartin Luther University Halle-Wittenberg · DEAmerican Cancer Society · USUniversity of Minnesota · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOvarian cancer is the third leading cause of cancer death among women in Ethiopia, with about 2,550 diagnosed cases and 2,000 deaths each year. The incidence and mortality rates of this disease have been increasing in Ethiopia and other parts of sub-Saharan Africa over the past decades because of changing lifestyle and reproductive factors. In this study, we describe the clinical characteristics, treatment patterns, and survival of patients with ovarian cancer in Ethiopia. MATERIALS AND

methodsThis retrospective cohort study included 485 patients diagnosed between January 2009 and October 2015 at Addis Ababa University Hospital, Zewditu Memorial Hospital, or registered in the Addis Ababa population-based cancer registry. Follow-up data were obtained via telephone. Primary endpoint was all-cause mortality.

resultsThe median age was 46 years (range, 11-95). The estimated 1- and 2-year overall survival rates were 78% (95% confidence interval [CI] 0.741-0.82.5) and 59% (95% CI, 0.538-0.646), respectively. Of those patients with result available (

conclusionOur study revealed substantial treatment gaps with respect to surgery and adequate chemotherapy. Higher stage, residual tumor and lack of chemotherapy impaired the outcome. Access to higher standards of ovarian cancer treatment is urgently needed in Ethiopia. IMPLICATIONS FOR PRACTICE: Ovarian cancer is often a fatal disease in high resource settings; now it is also becoming important in Ethiopia. This study included 485 women with malignant ovarian tumors treated in Addis Ababa who had a mean age of only 46 years because of the young population structure. Three quarters had the typical epithelial cancer, with half presenting with advanced stage III and IV. Improved oncologic surgery and sufficient chemotherapy could possibly improve their outcome. The relatively high proportion of women with nonepithelial cancer need adequate treatment options to have good prognosis.

Indexed as

AdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChildEthiopiaFemaleFollow-Up StudiesHumansHysterectomyMiddle AgedOvarian NeoplasmsOvariectomyPrognosisRetrospective StudiesAfricaEthiopiaOvarian cancerOvarian neoplasmsSurvival

Identifiers

PMID31023861
PMCPMC6656495
OpenAlexW2941472351

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.